A Phase 4 interventional study of Central venous catheter insertion in Shock, sponsored by Montefiore Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Montefiore Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Shock with a site in United States — 12 open to participants now, 18 under way, 1 of them phase 3. Shock · United States.
Among the 83 studies in Shock with a site in United States, this one is the 20th largest by planned enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2022, is one of 9 in phase 4, reaches primary completion later than 12 of the 17 other live ones, and was the 70th registered.
487 studies on the registry are indexed under Shock; 107 are open to participants now.
Browse Shock studies →12 of the 83 studies in Shock with a site in United States are open now. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages up to 28 days
Kingman Regional Medical Center · Sites in United States
Ages 18+
Jason Sperry · Sites in United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in United States, Canada
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Shock studies recruiting now, 52 (76%) set no upper age limit and 11 (16%) stop at 75 or younger; 9 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 10 · Phase 4 9
First in 2001; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 100 across 229 interventional studies indexed under Shock.
Median enrollment 100 across the 49 interventional studies, 106 across the 34 observational. Of the 58 that completed or were terminated, 21 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 83 have an industry lead sponsor. The 10 most frequent:
Montefiore Medical Center is the lead sponsor of 417 studies on the registry; 69 are open to participants now.
Of its 89 completed or terminated interventional studies of FDA-regulated products, 77 (87%) have results posted.
Montefiore Medical Center has 3 studies filed under Shock — fewer than ten, so there is no comparison to draw.
6 of the studies in Shock with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06895213Mayo ClinicEvaluation of Plasma Renin Concentrations in Cardiac Surgery | 2026-12 |
| NCT05267886Ottawa Heart Institute Research CorporationCAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock | 2026-12 |
| NCT07425587Bluejay Diagnostics, Inc.Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study | 2026-12-30 |
| NCT06654895Bluejay Diagnostics, Inc.Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study | 2026-12-31 |
| NCT06713668Vanderbilt University Medical CenterAugmented Pacing for Shock in the Cardiac Intensive Care Unit | 2027-04-22 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies in Shock with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Two different techniques for placing a central venous catheter will be compared. The studyu team hypothesizes that clinicians randomized to the peripheral catheter technique will have higher first attempt success rates, fewer procedural complications, and a shorter mean time to procedure completion than physicians assigned to wire through hollow bore needle.
Central venous catheterization (CVC) is a lifesaving procedure carried out by emergency and acute care physicians to access proximal blood vessels in order to deliver medications, blood products and other resuscitative agents. Typically, this access is achieved by threading a wire through a hollow bore needle and then placing the central venous catheter over the wire. This procedure, called the Seldinger technique, results in the cannulation of the femoral or internal jugular veins. Nowadays, physicians use concurrent ultrasound guidance rather than an anatomic landmark-based approach to increase the success rate of central venous catheterization. The wire through hollow bore needle approach requires the use of two hands to hold the needle in the vessel in order to pass a guidewire. When done under ultrasound guidance, this requires dropping the ultrasound probe in order to have both hands available to achieve vessel cannulation.
Recent research has demonstrated that cannulation of central veins can be obtained by first using a peripheral intravenous catheter rather than a hollow bore needle. This technique requires just one hand, thereby allowing the physician to continue use of the ultrasound. Furthermore, the peripheral intravenous catheter is more stable within the vein than the hollow bore needle and less likely than the needle to damage the vessel wall when the catheter is jiggled. This is the same technique used to place mid-lines, a hybrid technique that incorporates the Seldinger technique and a peripheral intravenous catheter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients in the emergency department who require ultrasound guided central line placement are eligible for participation and will be referred for participation in the study by the clinical team.
Exclusion Criteria:
Or for any clinical feature that would interfere with obtaining including dementia, delirium, or encephalopathy, as determined by the clinical attending physician.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The conventional hollow bore needle on a syringe will be used
Procedure: Central venous catheter insertion
A peripheral intravenous catheter will be used to obtain initial central venous access
Procedure: Central venous catheter insertion
The clinical team will use the technique to establish central venous access
Only 1 attempt
The frequency with which the central line can be placed with only one attempt will be summarized. Each attempt is defined by skin penetration
Time frame: 20 minutes
Unable to place central line
The frequency with which the clinical team is unable to place the central line at that clinical site using the assigned technique will be summarized by study arm.
Time frame: 20 minutes
Number of attempts
Total number of required attempts (skin penetration) will be summarized by study arm.
Time frame: 20 minutes
Number of attempted guidewire passages
Total number of attempted guidewire passages, defined as the number of times a guidewire must be attempted to be passed, will be determined. Results will be summarized by study arm.
Time frame: 20 minutes
Time taken for completion of the procedure
The duration of time from skin penetration to wire out will be summarized by study arm using basic descriptive statistics.
Time frame: 20 minutes
Procedure-related adverse events
Procedure related adverse events including pneumothorax, incorrect vessel cannulation, and bleeding requiring application of pressure will be summarized by study arm.
Time frame: 20 minutes
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.